QUILT-3.047: NANT Head and Neck Squamous Cell Carcinoma (HNSCC) Vaccine: Combination Immunotherapy in Subjects With HNSCC Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy

• Status: Withdrawn
• Trial end date: 2019-03-01

Summary

This is a phase 1b/2 study to evaluate the safety and efficacy of metronomic combination therapy in subjects with HNSCC who have progressed on or after previous chemotherapy and anti-PD-1/PD-L1 therapy.

• Phase: Phase 1/Phase 2

Details

• Lead Sponsor: ImmunityBio, Inc.; NantCell, Inc.
• Treatments: Avelumab; Bevacizumab; Capecitabine; Cetuximab; Cisplatin; Cyclophosphamide; Fluorouracil; Fulvestrant; Leucovorin; Nivolumab; Paclitaxel; Vaccines